Tickerlog
Monday 28th of March 2022 02:28:46 AM

AstraZeneca's Evusheld gets approval in EU to prevent COVID-19

AstraZeneca production plant Roland Magnusson/iStock Editorial via Getty Images
  • The European Commission approved AstraZeneca's (NASDAQ:AZN) antibody cocktail Evusheld for preventing COVID-19 in people aged 12 years and older weighing at least 40 kg.
  • The approval follows the recommendation made by a panel of the European Medicines Agency last week.
  • The recommended dose of Evusheld in Europe is 150mg of tixagevimab and 150mg of cilgavimab, administered as two separate sequential intramuscular injections.
  • The approval was backed by data from a phase 3 trial, dubbed PROVENT, which showed a 77% reduction in the risk of developing symptomatic COVID-19 compared to placebo at the primary analysis and an 83% reduction at a six-month median analysis, with protection from the virus lasting at least six months.
  • Evusheld is already approved in the U.K. and U.S.

AZN

Top gainers today
Top losers today